Works by Chitu, Dana


Results: 10
    1
    2

    Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00850-6
    By:
    • Hilberink, Jacobien R.;
    • van Zeventer, Isabelle A.;
    • Chitu, Dana A.;
    • Pabst, Thomas;
    • Klein, Saskia K.;
    • Stussi, Georg;
    • Griskevicius, Laimonas;
    • Valk, Peter J. M.;
    • Cloos, Jacqueline;
    • van de Loosdrecht, Arjan A.;
    • Breems, Dimitri;
    • van Lammeren-Venema, Danielle;
    • Boersma, Rinske;
    • Jongen-Lavrencic, Mojca;
    • Fehr, Martin;
    • Hoogendoorn, Mels;
    • Manz, Markus G.;
    • Söhne, Maaike;
    • van Marwijk Kooy, Rien;
    • Deeren, Dries
    Publication type:
    Article
    3

    Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00850-6
    By:
    • Hilberink, Jacobien R.;
    • van Zeventer, Isabelle A.;
    • Chitu, Dana A.;
    • Pabst, Thomas;
    • Klein, Saskia K.;
    • Stussi, Georg;
    • Griskevicius, Laimonas;
    • Valk, Peter J. M.;
    • Cloos, Jacqueline;
    • van de Loosdrecht, Arjan A.;
    • Breems, Dimitri;
    • van Lammeren-Venema, Danielle;
    • Boersma, Rinske;
    • Jongen-Lavrencic, Mojca;
    • Fehr, Martin;
    • Hoogendoorn, Mels;
    • Manz, Markus G.;
    • Söhne, Maaike;
    • van Marwijk Kooy, Rien;
    • Deeren, Dries
    Publication type:
    Article
    4
    5

    Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.

    Published in:
    Annals of Hematology, 2025, v. 104, n. 1, p. 361, doi. 10.1007/s00277-024-06033-y
    By:
    • Huls, Gerwin;
    • Chitu, Dana A.;
    • Tick, Lidwine;
    • Boersma, Rinske;
    • Breems, Dimitri;
    • Herbers, Alexandra;
    • Klein, Saskia K.;
    • de Jonge, Suzan;
    • Westerweel, Peter E.;
    • Cruijsen, Marjan;
    • Hoogendoorn, Mels;
    • Cuijpers, Marlous;
    • Deeren, Dries;
    • Bailly, Benjamin;
    • Visser, Otto;
    • van Rhenen, Anna;
    • Posthuma, Eduard F. M.;
    • Valk, Peter J. M.;
    • Cloos, Jacqueline;
    • Ammatuna, Emanuele
    Publication type:
    Article
    6

    Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial.

    Published in:
    Genes, Chromosomes & Cancer, 2017, v. 56, n. 7, p. 524, doi. 10.1002/gcc.22455
    By:
    • Stevens‐Kroef, Marian J.;
    • Olde Weghuis, Daniel;
    • ElIdrissi‐Zaynoun, Najat;
    • van der Reijden, Bert;
    • Cremers, Eline M. P.;
    • Alhan, Canan;
    • Westers, Theresia M.;
    • Visser‐Wisselaar, Heleen A.;
    • Chitu, Dana A.;
    • Cunha, Sonia M.;
    • Vellenga, Edo;
    • Klein, Saskia K.;
    • Wijermans, Pierre;
    • de Greef, Georgine E.;
    • Schaafsma, M. Ron;
    • Muus, Petra;
    • Ossenkoppele, Gert J.;
    • van de Loosdrecht, Arjan A.;
    • Jansen, Joop H.
    Publication type:
    Article
    7
    8

    Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.

    Published in:
    British Journal of Haematology, 2020, v. 190, n. 3, p. 385, doi. 10.1111/bjh.16567
    By:
    • Doorduijn, Jeanette K.;
    • Zijlstra, Josee M.;
    • Lugtenburg, Pieternella J.;
    • Kersten, Marie Josee;
    • Böhmer, Lara H.;
    • Minnema, Monique C.;
    • MacKenzie, Marius A.;
    • van Marwijk Kooij, Rien;
    • Jongh, Eva;
    • Snijders, Tjeerd J.F.;
    • Weerdt, Okke;
    • Gelder, Michel;
    • Hoogendoorn, Mels;
    • Leys, Rineke B.L.;
    • Kibbelaar, Robby E.;
    • Jong, Daphne;
    • Chitu, Dana A.;
    • Van't Veer, Mars B.;
    • Kluin‐Nelemans, Hanneke C.
    Publication type:
    Article
    9

    Rituximab‐PECC induction followed by <sup>90</sup>Y‐ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.

    Published in:
    British Journal of Haematology, 2019, v. 187, n. 3, p. 347, doi. 10.1111/bjh.16087
    By:
    • Lugtenburg, Pieternella J.;
    • Zijlstra, Josee M.;
    • Doorduijn, Jeanette K.;
    • Böhmer, Lara H.;
    • Hoogendoorn, Mels;
    • Berenschot, Henriette W.;
    • Beeker, Aart;
    • van der Burg‐de Graauw, Nicole C.;
    • Schouten, Harry C.;
    • Bilgin, Yavuz M.;
    • Kersten, Marie‐Jose;
    • Koene, Harry R.;
    • Herbers, Alexandra H. E.;
    • de Jong, Daphne;
    • Hijmering, Nathalie;
    • Lam, King H.;
    • Chiţu, Dana;
    • Brouwer, Rolf E.;
    • van Imhoff, Gustaaf W.
    Publication type:
    Article
    10